Development of stability indicating, validated single dissolution method for simultaneous estimation of clopidogrel bisulfate and rivaroxaban in tablet dosage formulation by RP-HPLC method
Keywords:
Dissolution, Method development, Validation, Rivaroxaban, Clopidogrel Bisulfate, Sink conditionAbstract
A dissolution method was developed for combination of two drugs which are already marketed as an individual product, Clopidogrel Bisulfate Tablets USP 75 mg and another is Rivaroxaban Tablets 10 mg & 20 mg. It was emphasized that both products have several advantages when given as combination therapy. Hence, the preference was given to develop a single dissolution method for the analysis of both the active components. This article presents a single dissolution method to accommodate both drugs. The method uses USP Type II Apparatus (paddles) at 75 rpm in 1000 mL of Acetate buffer (pH 4.5) medium containing 1% Sodium Lauryl Sulfate as surfactant at 37 °C± 0.5°C . This dissolution methodology provides good dissolution profiles for both Clopidogrel Bisulfate and Rivaroxaban and is able to discriminate the changes in composition, manufacturing process and stability for the combination tablets. To quantitate both drugs simultaneously, a rapid isocratic reversed-phase liquid chromatographic method was developed and validated.
Downloads
References
Jacbson AK. Platelet ADP receptor antagonists: ticlopidine and clopidogrel.NCBI Best Pract. Res. Clin. Haematol 2004 , 17 (1), 55-64.
SanjeevaY, Sivakumar A, Sameer G. Navalgund. Physico-chemical studies on stability of Clopidogrel tablet formulations.Int J Pharm Bio Sci. 2012 Oct; 3(4): (P) 433 – 439
USP monograph. Clopidrogel Bisulfate USP 32-NF 27: (P) 1992
Pravin B. Cholke, Raihan Ahmed,S. Z. Chemate, K. R. Jadhav.Development and Validation of Spectrophotometric Method for Clopidogrel bisulfate in pure and in film coated tablet dosage form. Arch. Appl. Sci. Res. 2012; 4 (1):59-64;
Zongyun Huang, Ruben Lozano1, Robert Francis, Anne-FrançoiseAubry, Alyson Steckbeck, Denis O. Sciascia.Development of a Single in Vitro Dissolution Method for a combination Trilayer Tablet Formulation of Clopidrogel and Pravastatin. Dissolution Technologies. Feb 2011; 12-19.
Pinaz A.Kasad, K.S. Muralikrishna. "Bayer's Xarelto Approved in Canada" (Press release). Bayer. "Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU". Bayer.
Pinaz A. Kasad, K.S. Muralikrishna. Design and Validation of Dissolution Profile of Rivaroxaban by Using RP-HPLC Method in Dosage Form. Asian J. Pharm. Ana. 2013; Vol. 3: Issue 3:Pg 75-78
CHMP Assessment report for Xarelto, European Medicine Agency Evaluation of Medicines For Human Use: Doc .Ref.: EMEA/543519/2008
Fernandez D, Penela D, Heras M.Contribution of the new oral anticoagulant to the treatment of acute coronary syndrome. Med Clin (Barc).2012 OCT;139 Suppl 2 : 41-45
Josilene Chaves RuelaCorrêa,Cristina Duarte Vianna-Soares,Hérida Regina NunesSalgado. Development and Validation of Dissolution Test for Fluconazole Capsules by HPLC and Derivative UV Spectrophotometry. Chromatography Research International. Volume 2012 (2012), Article ID 610427
Paulo Costa, Sousa Lobo JM.Influence of dissolution medium agitation on release profiles of sustained-release tablets. Drug Development and Industrial Pharmacy.2001; vol. 27,Issue 8: 811–817
Mehta J, Patidar K, Patel V, Kshatri N,Vyas N. Development & validation of an in vitro dissolution method with HPLC analysis for misoprostol in formulated dosage form. Analytical Methods.2010; vol. 2, no. 1:72–75
FDA, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, Food and Drug Administration, Rockville, MD, 1997
Marcolongo R., Dissolução de medicamentos: fundamentos, aplicações, aspectosregulatórios e perspectivasnaáreafarmacêutica, Thesis -Drugs and Medicines Post Graduation Program, University of São Paulo, São Paulo, Brazil, June 2011.
The United States Pharmacopoeia, Pharmacopeial Forum, 2004, 30,351–363
Jigar Mehta, Kanhaiyalal Patidar, Vipul Patel, Nayan K Shatri, Niranjan Vyas. Development & validation of an in vitro dissolution method with HPLC analysis for misoprostol in formulated dosage form. Anal. Methods.2010;Vol 2,no.1: 72–75
Lagace M, Gravelle L, Di Maso M, McClintock S. Developing a discriminating dissolution procedure for a dual active pharmaceutical product with unique solubility characteristics. Dissolution Technologies.2004;2:13-7
Soni T, Nagda C, Gandhi T, Chotai NP. Development of discriminating method for dissolution of Aceclofenac marketed formulations. Dissolution Technologies. 2008;5: 31-35
Panikumar AD, Venkat Raju Y, Sunitha G, Sathesh B PR, Subrahmanyam CVS . Development of biorelevant and discriminating dissolution media for Efavirenz and its formulations. Asian J Pharm Clin Res. 2012; 5, Suppl 3: 220-223
Qingxi W, Nikoletta F, Yun M. Biorelevant dissolution methodology and application in drug development. Dissolut Technol. Aug 2009; 6-12
Zoeller T, Klein S. Simplified biorelevant media for screening dissolution performance of poorly soluble drugs. Dissolut Technol. 2007; 11: 8-13
Dressman J, Kramer J. Pharmaceutical dissolution Testing. 1st ed.London: Taylor and Francies group.2007; 92-98
Rohrs BR. Dissolution method development of poorly soluble compounds. DissolutTechnol 2001; 8: 1-5
Tenhoor NC, Bakatselou V, Dressman J. Solubility of Mefenamic acid under simulated fed and fasted state conditions. J Pharm Res 1991;8:1203-1205
Jogia H, Mehta T, Patel M. Evaluation of dissolution media containing a novel synthetic surfactant by in vitro testing of BCS class II drugs. DissolutTechnol 2009;8:14-19
AmidonGL, Lennernas H,VP Shah,J. R. Crison.A Theoretical Basis For a Biopharmaceutic Drug Classification.The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability. 1995; Pharmaceutical Research.Vol12 no.3:413-420
Marc Lindenberg,Sabine Kopp, Jennifer B Dressman. Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the biopharmaceutics classification system. European Journal of Pharmaceutics and Biopharmaceutics. 2004; 58 (2): 265-278
Takagi T, Ramchandran C, Bermejo M,Gordon L Amidon. A provisional biopharmaceutical classification of the Top 200 oral drug products in United States, Great Britain, Spain and Japan. Molecular Pharmaceutics. 2006; 3(6): 631 – 643
Satyanarayana PVV, Alavala SM. New Spectrophotometric methods for the quantitative estimation of Rivaroxaban in formulations. International Journal of Research and Reviews in Pharmacy and Applied science; 2(4): 611-620
Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M.Determination of Rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of inter assay variability. Journal of Thrombosis and Thrombolysis, J Thromb Thrombolysis 2011; 32 (3): 267–271
Satyanarayana PVV, Alavala SM, RP-HPLC method development and validation for the analysis of rivaroxaban in pharmaceutical dosage forms.2012;2 (1): 226-231
Souri E, Mottaghi S. Development of a Stability-Indicating HPLC Method and a Dissolution Test for Rivaroxaban Dosage Forms. Acta Chromatographica.2016;DOI: 10.1556/1326.
Pravin B C, Ahmed R. Development and Validation of Spectrophotometric Method for Clopidogrel bisulfate in pure and in film coated tablet dosage form. Arch. Appl. Sci. Res. 2012; 4 (1): 59-64
Singh SS, Sharma K, Barot D, Mohan P R, Lohray V B. Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. J. Chromatogr. B Analyt Technol Biomed Life Sci. 2005; 821 (2): 173–180
Ksycinska H, Rudzki P, Bukowska-Kiliszek M. Determination of Clopidogrel metabolite (SR26334) in human plasma by LC–MS. J. Pharm. Biomed. Anal. 2006; 41(2): 533–539
Gomez Y, Adams E, Hoogmartens J, Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J. Pharm. & Biomed. Anal. 2004; 34 (2), 341–348
Mitakos A, Panderi I. A validated LC method for the determination of Clopidogrel in pharmaceutical preparations. J. Pharm. Biomed. Anal. 2002; 28 (3–4): 431–438
Shah VP. In Vitro Dissolution Profile of Water Insoluble Drug Dosage Forms in the Presence of Surfactants. Pharmaceutical Research. 1989; 6: 612-618
Robert CW. Setting Dissolution Specifications. Dissolution Technologies. August 1997
Dissolution Test for Tablets and Capsules (Dissolution Test for Solid Dosage Forms) Ph.Eur. Appendix XII B.
William Brown, Margareth Marques. Question and Answer Section. Dissolution Technologies. May 2013
Published
How to Cite
Issue
Section
Copyright (c) 2020 Rupali Sajjanwar, Shyamala Bhaskaran, Kulesh Kakati, Shailendra Kumar Jha
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
